Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
XP Health grabs $32M to bring employees more affordable vision care

From TechCrunch

By Marina Temkin

September 12, 2024

XP Health grabs $32M to bring employees more affordable vision care

XP Health grabs $32M to bring employees more affordable vision care

Antonio Moraes, the grandson of a late prominent Brazilian billionaire, was never interested in joining the family-owned conglomerate of construction companies and a bank. Shortly after graduating from college, he founded one of Brazil’s first impact funds, which invested primarily in companies that made healthcare more accessible and affordable.

But while attending Stanford University, where Moraes received a master’s in business administration and healthcare policy, he realized that instead of investing in impactful companies, he wanted to start his own.

As a part of an entrepreneurship class, Moraes and his co-founder, an engineering grad student, James Wong, visited multiple eyeglass manufacturing factories in China. They discovered that designer frames that sell for as much as $600 in the US cost only about $10 to produce. “We thought there’s something very wrong with these markups,” Moraes told TechCrunch.

Since vision care and eyeglasses are expensive, many employees buy frames with their vision insurance, but the benefits typically don’t cover all the costs, Moraes said. “With vision insurance, people expect not to pay anything, but then they leave the optician’s office with a $300 out-of-pocket bill.”

Moraes and Wong started XP Health in late 2018, but during the pandemic, they shifted the startup’s focus to a digital-first, AI-driven platform that offers employees eye exams and eyewear benefits at significantly lower costs than existing vision insurance plans.

On Thursday, XP Health announced a $33.2 million Series B led by QED Investors with participation from Canvas Ventures, American Family Ventures, HC9 Ventures, Valor Capital Group, and Manchester Story. The round comes less than two years after XP Health’s $17.1 million Series A.

XP Health members who buy eyeglasses virtually can save as much as 69% off the retail price, Moraes said. The company claims not to markup the frames or lenses sourced directly from factories in Asia. Instead, XP Health generates its revenue through recurring membership fees.

“In many cases, our members pay $0 for a pair of high-quality designer frames with the best-in-class lenses, and for the eye exam as well,” Moraes said.

XP Health’s AI-powered platform uses facial recognition to recommend glasses that fit the member’s style and face shape.

Members can also buy glasses from physical eyewear retailers at a discount, but Moares emphasized that a similar frame can cost as much as two to three times less if purchased from the company’s online platform.

Over the last two years, the company has expanded its business customer roster from 30 to over 3,000 business customers, including DocuSign, Navistar, Chegg and Sequoia Consulting, who offer XP Health as a benefit to their employees. XP Health also has formed strategic partnerships with insurance providers such as Guardian Life Insurance, which provides vision benefits to small businesses.

Of course, XP Health is not the only company that’s taking out the middleman in eyewear. This is already a crowded market. Warby Parker sells directly to consumers as does Eyebuydirect, Firmoo, Pair Eyewear, and Zenni, to name a few other options. But Moares claims XP Health is the only startup that’s taking on incumbent vision insurance providers, a market that’s dominated by VSP and EyeMed Vision Care.

Yet, XP Health doesn’t consider itself to be an insurance company. That’s because what these companies offer is not insurance in a traditional sense. “There’s no real risk,” Moares said. “It’s a corporate benefit.”

View original article on techcrunch.com

Most Recent

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

As Chinese AI models grow in capability and popularity among U.S. companies, the arguing over what should be done about them has reached a fever pitch.

Jul 22, 2026

Cascade raises $3.5M to help construction firms find and win projects

Cascade raises $3.5M to help construction firms find and win projects

a16z Speedrun, Ada Ventures, and Snowball VC have invested in Cascade's $3.5 million seed round.

Jul 22, 2026

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

We’ve compiled an overview of some of the top alternative browsers available today aiming to challenge Chrome and Safari.

Jul 22, 2026

Glow emerges from stealth at $1.2B valuation to challenge endpoint security in the AI era

Glow emerges from stealth at $1.2B valuation to challenge endpoint security in the AI era

Glow is targeting a new class of endpoint risks created by the rapid adoption of AI agents and developer tools inside enterprises.

Jul 22, 2026

Similar Posts

No similar posts found for this article.

Most Recent

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

As Chinese AI models grow in capability and popularity among U.S. companies, the arguing over what should be done about them has reached a fever pitch.

Jul 22, 2026

Cascade raises $3.5M to help construction firms find and win projects

Cascade raises $3.5M to help construction firms find and win projects

a16z Speedrun, Ada Ventures, and Snowball VC have invested in Cascade's $3.5 million seed round.

Jul 22, 2026

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

We’ve compiled an overview of some of the top alternative browsers available today aiming to challenge Chrome and Safari.

Jul 22, 2026

Glow emerges from stealth at $1.2B valuation to challenge endpoint security in the AI era

Glow emerges from stealth at $1.2B valuation to challenge endpoint security in the AI era

Glow is targeting a new class of endpoint risks created by the rapid adoption of AI agents and developer tools inside enterprises.

Jul 22, 2026

Similar Posts

No similar posts found for this article.